{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:50:01Z","timestamp":1791528601638,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ejmech.2022.114479","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T07:18:15Z","timestamp":1653463095000},"page":"114479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia"],"prefix":"10.1016","volume":"238","author":[{"given":"Kaijun","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaocong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxuan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-3071","authenticated-orcid":false,"given":"Xiaojin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114479_bib1","first-page":"1238","volume":"389","author":"Webster","year":"2017","journal-title":"Chron. Kidney Dis. Lancet"},{"key":"10.1016\/j.ejmech.2022.114479_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000455387","article-title":"History of erythropoiesis-stimulating agents, the development of biosimilars, and the future of anemia treatment in nephrology","volume":"45","author":"Kalantar\u2013Zadeh","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ejmech.2022.114479_bib3","first-page":"195","article-title":"Erythropoietin stimulating agents in the management of anemia of chronic kidney disease","volume":"2","author":"Hayat","year":"2008","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.ejmech.2022.114479_bib4","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/13543784.2018.1493455","article-title":"Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF\u2013PHI) for the treatment of anemia associated with chronic kidney disease","volume":"27","author":"Del Vecchio","year":"2018","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2022.114479_bib5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrneph.2015.82","article-title":"Anaemia in kidney disease: harnessing hypoxia responses for therapy","volume":"11","author":"Koury","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejmech.2022.114479_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrm1366","article-title":"Oxygen sensing by HIF hydroxylases","volume":"5","author":"Schofield","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2022.114479_bib7","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.1021\/jm400386j","article-title":"Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses","volume":"56","author":"Rabinowitz","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114479_bib8","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1021\/acs.jmedchem.8b01596","article-title":"Small\u2013molecule modulators of the hypoxia-inducible factor pathway: development and therapeutic applications","volume":"62","author":"Li","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114479_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.tibs.2012.10.004","article-title":"Emerging novel functions of the oxygen-sensing prolyl hydroxylase domain enzymes","volume":"38","author":"Wong","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2022.114479_bib10","doi-asserted-by":"crossref","first-page":"9814","DOI":"10.1073\/pnas.0601283103","article-title":"Cellular oxygen sensing: crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2)","volume":"103","author":"McDonough","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2022.114479_bib11","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.str.2009.06.002","article-title":"Structural basis for binding of hypoxia-inducible factor to the oxygen-sensing prolyl hydroxylases","volume":"17","author":"Chowdhury","year":"2009","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2022.114479_bib12","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.drudis.2020.04.017","article-title":"The prolyl hydroxylase inhibitor roxadustat: paradigm in drug discovery and prospects for clinical application beyond anemia","volume":"25","author":"Su","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2022.114479_bib13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.117.242503","article-title":"Discovery and preclinical characterization of GSK1278863 (daprodustat), a small molecule hypoxia inducible factor-prolyl hydroxylase inhibitor for anemia","volume":"363","author":"Ariazi","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114479_bib14","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/cmdc.201700783","article-title":"Discovery of molidustat (BAY 85-3934): a small-molecule oral HIF-prolyl hydroxylase (HIF\u2013PH) inhibitor for the treatment of renal anemia","volume":"13","author":"Beck","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.114479_bib15","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1021\/acsmedchemlett.7b00404","article-title":"Discovery of JTZ-951: a HIF prolyl hydroxylase inhibitor for the treatment of renal anemia","volume":"8","author":"Ogoshi","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114479_bib16","doi-asserted-by":"crossref","first-page":"11039","DOI":"10.1021\/acs.jmedchem.6b01242","article-title":"Discovery of N-[bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an orally active pan-inhibitor of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia","volume":"59","author":"Debenham","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114479_bib17","doi-asserted-by":"crossref","first-page":"10045","DOI":"10.1021\/acs.jmedchem.0c01161","article-title":"Discovery of clinical candidate (5-(3-(4-chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an orally bioavailable prolyl hydroxylase inhibitor for the treatment of anemia","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114479_bib18","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1021\/jm201542d","article-title":"1,3,8-triazaspiro[4.5]decane-2,4-diones as efficacious pan-Inhibitors of hypoxia-inducible factor prolyl hydroxylase 1\u20133 (HIF PHD1\u20133) for the treatment of anemia","volume":"55","author":"Vachal","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114479_bib19","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1021\/ml100198y","article-title":"Benzimidazole-2-pyrazole HIF prolyl 4-hydroxylase inhibitors as oral erythropoietin secretagogues","volume":"1","author":"Rosen","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114479_bib20","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1021\/acs.jmedchem.7b01686","article-title":"Prolyl hydroxylase inhibitors: a breakthrough in the therapy of anemia associated with chronic diseases","volume":"61","author":"Joharapurkar","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114479_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40265-019-01077-1","article-title":"Roxadustat: first global approval","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114479_bib22","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s40265-020-01384-y","article-title":"Daprodustat: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114479_bib23","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s40265-020-01383-z","article-title":"Vadadustat: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114479_bib24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40265-020-01444-3","article-title":"Enarodustat: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114479_bib25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40262-017-0551-3","article-title":"Phase I clinical study of ZYAN1, a novel prolyl-hydroxylase (PHD) inhibitor to evaluate the safety, tolerability, and pharmacokinetics following oral administration in healthy volunteers","volume":"57","author":"Kansagra","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2022.114479_bib26","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000500232","article-title":"Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study","volume":"49","author":"Parmar","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ejmech.2022.114479_bib27","doi-asserted-by":"crossref","first-page":"14199","DOI":"10.1039\/D0CC06353C","article-title":"A small-molecule probe for monitoring binding to prolyl hydroxylase domain 2 by fluorescence polarisation","volume":"56","author":"Li","year":"2020","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2022.114479_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12673","article-title":"Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases","volume":"7","author":"Chowdhury","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2022.114479_bib29","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1063\/1.464304","article-title":"A new mixing of Hartree-Fock and local density\u2010functional theories","volume":"98","author":"Becke","year":"1993","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejmech.2022.114479_bib30","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1063\/1.464913","article-title":"Density\u2010functional thermochemistry. III. The role of exact exchange","volume":"98","author":"Becke","year":"1993","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejmech.2022.114479_bib31","author":"Frisch","year":"2016"},{"key":"10.1016\/j.ejmech.2022.114479_bib32","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1021\/acs.jmedchem.8b00549","article-title":"Click chemistry-based discovery of [3-hydroxy-5-(1H-1,2,3-triazol-4-yl)picolinoyl]glycines as orally active hypoxia-inducing factor prolyl hydroxylase inhibitors with favorable safety profiles for the treatment of anemia","volume":"61","author":"Wu","year":"2018","journal-title":"J. Med. Chem."}],"updated-by":[{"DOI":"10.1016\/j.ejmech.2023.115692","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T00:00:00Z","timestamp":1699142400000}}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422003816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422003816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T14:13:04Z","timestamp":1728396784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422003816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":32,"alternative-id":["S0223523422003816"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114479","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejmech.2023.115692","asserted-by":"object"}]},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114479"}}